Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: BMS | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: BMS

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 

2Q Revenues: $4.9 billion (+1%)

2Q Earnings: $706 million (+6%)

YTD Revenues: $9.4 billion (-1%)

YTD Earnings: $1.4 billion (flat)

Comments: Worldwide pharmaceutical sales were flat at $3.9 billion. U.S. pharmaceutical sales increased 2% to $2.2 billion due to growth of key products and sales of newer products Baraclude, (increased to $59 million, up from $14 million 2Q2006) Orencia (increased to $55 million, up from $18 million) and Sprycel ($35 million, up from $21 million), partially offset by the impact of increased generic competition for Pravachol (down 59% to $132 million). Sales of Plavix and Avapro/Avalide, part of the company’s alliance with sanofi-aventis, increased 4% to $1.2 billion and increased 6% to $297 million, respectively. R&D expenses increased 5% to $778 million. In the quarter, the company’s NDA for ixabepilone was accepted by the FDA and Orencia was approved by the EMEA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters